Table of contents
Divi’s Laboratories is one of India’s largest custom API and CRAMS (Contract Research and Manufacturing Services) manufacturers, supplying active pharmaceutical ingredients to global pharma majors. This piece walks through the numbers a fundamentals-first reader should check before forming a long-term view.
Business overview
Divi’s operates two broad segments — generic APIs and custom synthesis for innovator pharma companies — plus a smaller nutraceuticals ingredients business. Revenue is meaningfully export-driven, so currency movements and global pharma capex cycles matter as much as domestic factors.
Revenue and earnings trend
| Metric | FY22 | FY23 | FY24 | FY25 | FY26E |
|---|---|---|---|---|---|
| Revenue (₹ Cr) | 8,306 | 7,392 | 7,706 | 9,200 | 10,450 |
| EBITDA Margin | 36.2% | 27.8% | 28.4% | 30.1% | 31.0% |
| Net Profit (₹ Cr) | 1,832 | 1,441 | 1,535 | 1,980 | 2,260 |
| EPS Growth YoY | +9% | -21% | +7% | +29% | +14% |
Earnings dipped through FY23 on raw-material cost pressure and a soft custom-synthesis cycle, before recovering into FY25–26 as margins normalised.
Balance sheet strength
| Check | Reading | Verdict |
|---|---|---|
| Debt-to-Equity | ~0.02x | Effectively debt-free |
| Interest Coverage | >100x | No solvency concern |
| ROCE (3-yr avg) | ~18-20% | Efficient capital use |
| ROE (3-yr avg) | ~15-17% | Healthy |
| Promoter Holding | ~51-52%, unpledged | Aligned, no pledge risk |
Valuation check
- P/E (TTM): Compare against the BSE Healthcare index average before treating any single number as “expensive” or “cheap” in isolation.
- EV/EBITDA: Cross-check against CRAMS peers (Syngene, Laurus Labs) rather than the market average, since business models differ.
- PEG ratio: Useful to sanity-check whether the P/E premium is justified by the forward growth rate.
Key risks to monitor
- Customer concentration — a handful of large innovator-pharma clients can move revenue meaningfully.
- Regulatory action — USFDA observations at any facility can halt shipments temporarily.
- Currency — a stronger rupee compresses export margins.
- Capex cycle — new facility ramp-up (e.g., Kakinada) affects near-term depreciation and margin.
Bottom line
Divi’s fundamentals — debt-free balance sheet, strong ROCE, aligned promoter holding — are genuinely high quality. The open question for a fundamentals-first investor is never “is this a good business” but “am I paying a reasonable price for that quality today.” Cross-check current valuation multiples against the company’s own 5-year average and against direct CRAMS peers before drawing a conclusion.
StockRanker Research Desk
The StockRanker Research Desk publishes independent, educational market and personal-finance content for Indian readers. We are not SEBI-registered analysts or advisers.
